Biography:

Prof. Hui WANG is the president of Women’s Hospital, Zhejiang University School of Medicine. He is a national high-level talent and “Qiushi” Distinguished Professor of Zhejiang University. He received his post-doctoral training in Zhejiang University and University of Pittsburgh, and is currently a chief physician of obstetrics and gynecology, and doctor supervisor. He is the project leader of the “14th Five-Year Plan” national key R&D program project "Reproductive Health and Women's and Children's Health Protection". Dr. Wang has published more than 30 articles in SCI journal, such as Nat Genet, JCI, CCR, Mol Ther etc. He is in charge of more than 10 ministerial and provincial projects, such as national key R&D program project, key project of national natural science foundation of China. He holds four national invention patents, one of which has completed industrial transformation. He won two first prizes of provincial-level Science and Technology Progress Award as a major participant.

Professional Memberships:

Vice-Chairman, Society Gynecological Oncology of Chinese Medical Association;

Committee member, Society of Gynecological Oncology of Chinese Medical Doctor Association;

Standing committee member, Society of Obstetrics and Gynecology of Zhejiang Medical Association;

Vice-Chairman, Society of Gynecological Oncology of Zhejiang Medical Association;

Vice-Chairman, Society of Obstetrics and Gynecology of Zhejiang Medical Doctor Association.

Clinical / Research Achievements:

Dr. Wang has devoted himself to the clinical and basic research of Obstetrics and Gynecology, with decade-long endeavor to surgery and comprehensive treatment of patients with gynecologic malignant tumors.

He has achieved a number of internationally-recognized innovations in the precision prevention and treatment of cervical cancer:

1. Mapping of HPV integration loci in cervical cancer and establishment of a new strategy for accurate screening and management of cervical cancer based on HPV integration detection.

2. Targeted HPV oncogenes molecular editing system to reverse cervical precancerous lesions.

Selected Publications：

1.  Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015; 47(2): 158-163.

2.  TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J Clin Invest. 2015; 125(1):425–436.

3.  SIX1 Promotes Tumor Lymphangiogenesis by Coordinating TGFβ Signals That Increase Expression of VEGF-C. Cancer Res. 2014; 74(19): 5597-5607.

4.  Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells. Clin Cancer Res. 2014; 20(24): 6495-6503.

5. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy. Mol Ther. 2018 Oct 3;26(10):2443-2455

6.  The application of CRISPR/Cas9 system in cervical carcinogenesis. Cancer Gene Therapy. 2021.

7. E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester). International journal of Nanomedicine. 2021,16;16:7609-7622.

8.  Detection of HPV and Human Chromosome Sites by Dual-Color Fluorescence In Situ Hybridization Reveals Recurrent HPV Integration Sites and Heterogeneity in Cervical Cancer. Frontiers in Oncology. 2021,5；11:734758.